Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: What can we learn from routine clinical practice?

Expert Review of Anticancer Therapy

Volumn 12, Issue 7, 2012, Pages 869-875

  Sacco, Rodolfo ^a,b   Bargellini, Irene ^a   Ginanni, Barbara ^a   Bertini, Marco ^a   Faggioni, Lorenzo ^a   Federici, Graziana ^a   Romano, Antonio ^a   Bertoni, Michele ^a   Metrangolo, Salvatore ^a   Altomare, Emanuele ^a,b   Parisi, Giuseppe ^a   Tumino, Emanuele ^a   Scaramuzzino, Antonio ^a   Bresci, Giampaolo ^a   Bartolozzi, Carlo ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

hepatocellular carcinoma; progression free rate; sorafenib

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SKIN REACTION; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LOCAL SKIN REACTION; LOW DRUG DOSE; MALE; NAUSEA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PATIENT ATTITUDE; PATIENT COMPLIANCE; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RADIOLOGICAL PARAMETERS; RASH; RECOMMENDED DRUG DOSE; REVIEW; SKIN DISEASE; SURVIVAL RATE; SURVIVAL TIME; TIME TO RADIOLOGICAL PROGRESSION;

AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DIARRHEA; DISEASE PROGRESSION; FATIGUE; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PYRIDINES; SKIN DISEASES; TREATMENT OUTCOME;

EID: 84864623897     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.58     Document Type: Review

References (16)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 53, 1020-1022 (2011).
3. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
4. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: A Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009).
5. Silverman SL. From randomized controlled trials to observational studies. Am. J. Med. 122, 114-120 (2009).
6. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35, 421-430 (2001).
7. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma:T he BCLC staging classification. Semin. Liver Dis. 19, 329-338 (1999).
8. Lencioni R, Llovet JM. Modified RECIST (MRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52-60 (2010).
9. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for Phase II trials in soft-tissue sarcomas. Eur. J. Cancer 38, 543-549 (2002).
10. Sacco R, Bargellini I, Gianluigi G et al. Complete response for advanced liver cancer during sorafenib therapy: Case report. BMC Gastroenterol. 11, 4 (2011).
11. Iavarone M, Cabibbo G, Piscaglia F et al.; SOFIA study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology 54, 2055-2063 (2011).
12. Lencioni R, Marrero J, Venook A, Ye SL, Kudo M. Design and rationale for the non-interventional Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) study. Int. J. Clin. Pract. 64, 1034-1041 (2010).
13. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol. 9, 117-123 (2008).
14. Keating GM, Santoro A. Sorafenib: A review of its use in advanced hepatocellular carcinoma. Drugs 69, 223-240 (2009).
15. Kim JE, Ryoo BY, Ryu MH et al. Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma. Oncology 82, 119-125 (2012).
16. Abbadessa G, Rimassa L, Pressiani T, Carrillo-Infante C, Cucchi E, Santoro A. Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib. World J. Gastroenterol. 17, 2450-2453 (2011).